Investor Presentaiton slide image

Investor Presentaiton

SAR-Bombesin clinical development ASCO 2022 Annual Meeting Abstract: 3092 | Poster: 82 C-BOBCAT: Results to be published at the 2022 ASCO Annual Meeting in June First-in-human pilot trial assessment of the diagnostic value of 64CU SAR-Bombesin PET/CT imaging for staging of hormone positive breast cancer patients with metastatic disease in comparison with standard of care imaging (CT, bone scan and 18F FDG PET/CT) Study Sponsor: St Vincent's Hospital, Sydney Pl: Prof. Louise Emmett • • Future milestones 64CU SAR-Bombesin diagnostic IND expected 1H 2022 Initial US diagnostic trial in PSMA negative prostate cancer patients to commence 2H 2022 67CU SAR-Bombesin therapy IND to be lodged 2H 2022 C-BOBCAT: One hour post 64CU-SAR-Bombesin administration in a breast cancer patient 18F FDG 64CU SAR-Bombesin A B • Data from the C-BOBCAT trial shows that 64Cu SAR-Bombesin is highly avid with a high tumour volume compared to 18F FDG in some patients Results indicate 64CU SAR-Bombesin may have a role in imaging patients with hormone positive breast cancer, particularly lobular subtype CLARITY 2014 MILE ST VINCENTS HOSPITAL SYDNEY PET/CT PET/CT CT CT PET PET 19
View entire presentation